/RAPP

RAPP Stock - Rapport Therapeutics, Inc. Common Stock

Q: What is the analyst price target for RAPP?

Analyst price target information is not currently available for RAPP.

Q: What is RAPP's market cap?

Market capitalization information is not currently available for RAPP.

Healthcare|Biotechnology|NASDAQ

$27.10+0.37%

+$0.10 (+0.37%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+67.9%upside

Target: $45.50

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for RAPP

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2022

FY2023

FY2024

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.65

52W High$42.27

52W Low$6.43

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022
Revenue	N/A	N/A	N/A
Gross Profit	$-839,000	$-112,000	$-15,000
Gross Margin	N/A	N/A	N/A
Operating Income	$-83,055,000	$-36,179,000	$-10,367,000
Net Income	$-78,307,000	$-34,786,000	$-10,652,000
Net Margin	N/A	N/A	N/A
EPS	$-0.38	$-0.19	$-0.05

Company Overview

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.

Visit Website

Earnings History & Surprises

RAPP

Beat Rate

83%

Last 6 quarters

Avg Surprise

-16.1%

EPS vs Estimate

Beats / Misses

5/1

Last 12 quarters

Latest EPS

$-0.71

Q4 2025

EPS Surprise History

Q4 23

No data

Q1 24

No data

Q3 24

-150.0%

$-1.70vs$-0.68

Q4 24

+12.3%

$-0.50vs$-0.57

Q1 25

+8.1%

$-0.57vs$-0.62

Q2 25

+11.7%

$-0.68vs$-0.77

Q3 25

+13.8%

$-0.75vs$-0.87

Q4 25

+7.8%

$-0.71vs$-0.77

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 6, 2026	—	—	—	—
Q1 2026	Mar 10, 2026	$-0.65	—	—	—
Q4 2025	Nov 6, 2025	$-0.77	$-0.71	+7.8%	✓ BEAT
Q3 2025	Aug 7, 2025	$-0.87	$-0.75	+13.8%	✓ BEAT
Q2 2025	May 8, 2025	$-0.77	$-0.68	+11.7%	✓ BEAT
Q1 2025	Mar 11, 2025	$-0.62	$-0.57	+8.1%	✓ BEAT
Q4 2024	Nov 7, 2024	$-0.57	$-0.50	+12.3%	✓ BEAT
Q3 2024	Aug 8, 2024	$-0.68	$-1.70	-150.0%	✗ MISS
Q1 2024	Mar 31, 2024	—	$-0.12	—	—
Q4 2023	Dec 31, 2023	—	$-0.07	—	—
Q3 2023	Sep 30, 2023	—	$-0.05	—	—
Q2 2023	Jun 29, 2023	—	$-0.03	—	—
Q1 2023	Mar 31, 2023	—	$-0.03	—	—

Frequently Asked Questions about RAPP

What is RAPP's current stock price?

Rapport Therapeutics, Inc. Common Stock (RAPP) is currently trading at $27.10 per share. The stock has moved +0.37% today.

What is the analyst price target for RAPP?

The average analyst price target for RAPP is $45.50, based on 1 analyst.

What sector is Rapport Therapeutics, Inc. Common Stock in?

Rapport Therapeutics, Inc. Common Stock operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is RAPP's market cap?

Rapport Therapeutics, Inc. Common Stock has a market capitalization of $0.99 billion, making it a small-cap company.

Does RAPP pay dividends?

No, Rapport Therapeutics, Inc. Common Stock does not currently pay a dividend to shareholders.